JP7788208B2 - キナーゼネットワークの阻害剤およびその使用 - Google Patents

キナーゼネットワークの阻害剤およびその使用

Info

Publication number
JP7788208B2
JP7788208B2 JP2019552978A JP2019552978A JP7788208B2 JP 7788208 B2 JP7788208 B2 JP 7788208B2 JP 2019552978 A JP2019552978 A JP 2019552978A JP 2019552978 A JP2019552978 A JP 2019552978A JP 7788208 B2 JP7788208 B2 JP 7788208B2
Authority
JP
Japan
Prior art keywords
tetrahydro
pyrazolo
phenanthridine
phenanthridin
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019552978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523282A5 (https=
JP2020523282A (ja
Inventor
オー． シンティム、ハーマン
ダヤル、ネートゥ
－ テメン、クレメント オポク
Original Assignee
パデュー リサーチ ファウンデイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パデュー リサーチ ファウンデイション filed Critical パデュー リサーチ ファウンデイション
Publication of JP2020523282A publication Critical patent/JP2020523282A/ja
Publication of JP2020523282A5 publication Critical patent/JP2020523282A5/ja
Priority to JP2022027439A priority Critical patent/JP7837179B2/ja
Priority to JP2022150644A priority patent/JP7668254B2/ja
Application granted granted Critical
Publication of JP7788208B2 publication Critical patent/JP7788208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019552978A 2017-03-29 2018-03-29 キナーゼネットワークの阻害剤およびその使用 Active JP7788208B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022027439A JP7837179B2 (ja) 2017-03-29 2022-02-25 キナーゼネットワークの阻害剤およびその使用
JP2022150644A JP7668254B2 (ja) 2017-03-29 2022-09-21 キナーゼネットワークの阻害剤およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762478069P 2017-03-29 2017-03-29
US62/478,069 2017-03-29
US201862616643P 2018-01-12 2018-01-12
US62/616,643 2018-01-12
PCT/US2018/024991 WO2018183586A1 (en) 2017-03-29 2018-03-29 Inhibitors of kinase networks and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022027439A Division JP7837179B2 (ja) 2017-03-29 2022-02-25 キナーゼネットワークの阻害剤およびその使用
JP2022150644A Division JP7668254B2 (ja) 2017-03-29 2022-09-21 キナーゼネットワークの阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2020523282A JP2020523282A (ja) 2020-08-06
JP2020523282A5 JP2020523282A5 (https=) 2020-09-17
JP7788208B2 true JP7788208B2 (ja) 2025-12-18

Family

ID=63677063

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019552978A Active JP7788208B2 (ja) 2017-03-29 2018-03-29 キナーゼネットワークの阻害剤およびその使用
JP2022027439A Active JP7837179B2 (ja) 2017-03-29 2022-02-25 キナーゼネットワークの阻害剤およびその使用
JP2022150644A Active JP7668254B2 (ja) 2017-03-29 2022-09-21 キナーゼネットワークの阻害剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022027439A Active JP7837179B2 (ja) 2017-03-29 2022-02-25 キナーゼネットワークの阻害剤およびその使用
JP2022150644A Active JP7668254B2 (ja) 2017-03-29 2022-09-21 キナーゼネットワークの阻害剤およびその使用

Country Status (6)

Country Link
US (3) US11040973B2 (https=)
EP (2) EP4233859A1 (https=)
JP (3) JP7788208B2 (https=)
CN (1) CN110662536B (https=)
CA (1) CA3056641A1 (https=)
WO (1) WO2018183586A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040973B2 (en) * 2017-03-29 2021-06-22 Purdue Research Foundation Inhibitors of kinase networks and uses thereof
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
US20220017908A1 (en) * 2018-11-20 2022-01-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
SG11202104331YA (en) 2018-12-11 2021-05-28 Theravance Biopharma R&D Ip Llc Naphthyridine and quinoline derivatives useful as alk5 inhibitors
WO2021061823A1 (en) * 2019-09-23 2021-04-01 Boragen, Inc. Chemical compounds
CN114728941A (zh) 2019-11-22 2022-07-08 施万生物制药研发Ip有限责任公司 作为alk5抑制剂的经取代的1,5-萘啶或喹啉
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
EP4175637A4 (en) * 2020-07-02 2024-08-07 Purdue Research Foundation Tetrahydro-3h-pyrazolo quinolone and tetrahydro-3h-pyrrolo[3,2-f]quinoline-containing compounds and uses thereof
KR20250004773A (ko) * 2022-04-20 2025-01-08 상하이 지멍 바이오파마 아이엔씨 Rho 관련 단백질 키나아제 억제제 및 이의 제조와 응용
CN117186002A (zh) * 2022-05-31 2023-12-08 江苏亚虹医药科技股份有限公司 7-氰基-8-羟基喹啉衍生物、其制备方法及其医药用途
EP4532471A2 (en) * 2022-06-02 2025-04-09 Purdue Research Foundation 4-(3h-pyrazolo[4,3-f]quinolin-7-yl)-n-(2-(dimethylamino)ethyl)benzamide- or hydroxamic acid compounds, compositions, and methods of use
WO2024206164A1 (en) * 2023-03-24 2024-10-03 Purdue Research Foundation 3H-PYRAZOLO[4.3:f] QUINOLINE-BASED COMPOUNDS AS STING ANTAGONISTS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542193A (ja) 1999-04-15 2002-12-10 ブリストル−マイヤーズ スクイブ カンパニー 環状タンパク質チロシンキナーゼ阻害剤
WO2011043359A1 (ja) 2009-10-06 2011-04-14 協和発酵キリン株式会社 芳香族複素環化合物を含有する医薬
JP2013542243A (ja) 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
WO2016112284A1 (en) 2015-01-09 2016-07-14 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947434A (en) * 1973-06-06 1976-03-30 Morton-Norwich Products, Inc. 9-(P-phenylazoanilino)-7-methyl-1H-imidazo[4,5-f]quinolines
CA1263378A (en) * 1985-01-08 1989-11-28 Robert James Alaimo Imidazo¬4,5-f|quinolines useful as immunomodulating agents
CA2134448A1 (en) * 1992-05-01 1993-11-02 Yoshinori Kyotani Quinoline derivative or salt thereof and remedy for cardiac diseases containing the same
US6228362B1 (en) * 1992-08-21 2001-05-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US20050080260A1 (en) * 2003-04-22 2005-04-14 Mills Randell L. Preparation of prodrugs for selective drug delivery
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060281771A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
CA2598216C (en) * 2005-06-17 2014-04-08 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2007005887A2 (en) * 2005-07-01 2007-01-11 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds, compositions and uses thereof
US9643965B2 (en) * 2014-09-17 2017-05-09 Celgene Quantical Research, Inc. Histone demethylase inhibitors
US11040973B2 (en) * 2017-03-29 2021-06-22 Purdue Research Foundation Inhibitors of kinase networks and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542193A (ja) 1999-04-15 2002-12-10 ブリストル−マイヤーズ スクイブ カンパニー 環状タンパク質チロシンキナーゼ阻害剤
WO2011043359A1 (ja) 2009-10-06 2011-04-14 協和発酵キリン株式会社 芳香族複素環化合物を含有する医薬
JP2013542243A (ja) 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
WO2016112284A1 (en) 2015-01-09 2016-07-14 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry, 2005, 13(15), p. 4733-4739
Chemistry - A European Journal, 2007, 13(27), p. 7584-7594
ChemMedChem, 2009, 4(3), p. 363-377
Journal of American Science, 2016, 12(5), p. 10-32
Journal of Heterocyclic Chemistry, 2014, 51(3), p. 830-834
Journal of Medicinal Chemistry, 2010, 53(22), p. 8047-8058
Journal of Medicinal Chemistry, 2013, 56(19), p. 7536-7551
Journal of Medicinal Chemistry, 2015, 58(20) , p. 7991-8010
Polycyclic Aromatic Compounds, 2016, 36(4), p. 275-283

Also Published As

Publication number Publication date
EP3600287A1 (en) 2020-02-05
US20200308173A1 (en) 2020-10-01
US12384782B2 (en) 2025-08-12
EP3600287B1 (en) 2023-07-05
CN110662536B (zh) 2023-06-23
US20210371420A1 (en) 2021-12-02
JP2022191259A (ja) 2022-12-27
EP4233859A1 (en) 2023-08-30
JP7668254B2 (ja) 2025-04-24
CN110662536A (zh) 2020-01-07
US11891391B2 (en) 2024-02-06
JP2022081529A (ja) 2022-05-31
JP7837179B2 (ja) 2026-03-30
EP3600287A4 (en) 2021-03-31
WO2018183586A1 (en) 2018-10-04
CA3056641A1 (en) 2018-10-04
US11040973B2 (en) 2021-06-22
JP2020523282A (ja) 2020-08-06
US20240208971A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
JP7668254B2 (ja) キナーゼネットワークの阻害剤およびその使用
CN101679425B (zh) 6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途
CN102803227B (zh) 吗啉基喹唑啉
KR101912475B1 (ko) Ｄｎａ-ｐｋ 저해제로서의 이미다조［4,5-ｃ］퀴놀린
CA3124678A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
US20090275570A1 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
KR101921764B1 (ko) 피라졸로-퀴놀린
CN112672997A (zh) 哒嗪酮衍生物
WO2008157791A2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
EP3166945B1 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
US20130065883A1 (en) Triazolo [4, 5- B] Pyridin Derivatives
CA3177164A1 (en) Bicyclic kinase inhibitors and uses thereof
TW202116770A (zh) 類鐸受體促效劑
CA3118093A1 (en) Small molecule inhibitors of dyrk1/clk and uses thereof
JP2020504139A (ja) キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途
JP2023545219A (ja) Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための７－アザインドール化合物
CA3231988A1 (en) Azaindazole macrocycle compound and use thereof
WO2023185073A1 (zh) Parp7抑制剂及其用途
WO2026064705A1 (en) 5/5-5/6-bisaryl compounds as transforming growth factor-β activated kinase inhibitors
US20250353862A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
CN121949337A (zh) 靶向泛素化降解alk的化合物及其药物组合物
HK40083035B (zh) Parp7抑制剂及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251208

R150 Certificate of patent or registration of utility model

Ref document number: 7788208

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150